BioPharmSignal logoBioPharmSignal

Biotech News

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsConference / presentation

– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs.

Open original release

Related news

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-05-21 21:01 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

IDYAIDEAYA Biosciences2026-05-26 10:00 EST

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-05-06 10:59 EST

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

View all latest news

Syndax Pharmaceuticals

Syndax Pharmaceuticals is an oncology company with programs in hematology and solid tumors, including targeted therapies and commercial assets. Its story blends launch execution with pipeline expansion.

Recent company news

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

SNDXSyndax Pharmaceuticals2026-05-21 21:01 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-05-20 11:00 EST

Syndax Announces Participation in Upcoming Investor Conferences

Stock data

Close
20.52 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States